# SANA — replay s6 — w4a16

## Metadata

ticker: SANA
arm: w4a16
sample: 6
served_name: financial-lora-w4a16
source_findings: eval/runs/raw/v924f-findings/SANA_local-model.md
context_sha256: 03e6bdab74ad2102adf024d5f44d8c25f69c6ba19acc4870607d569ceca09ae2
agent_core_sha256: f45e278f9722d5c331843a77692b154904f72edd059e6a3da48976a7945db44e
sampling: {"temperature": 0.1, "max_tokens": 512, "top_p": 0.8, "top_k": 20, "repetition_penalty": 1.1, "min_p": 0.0}
endpoint: http://localhost:30880
generated_utc: 2026-09-30T04:53:35Z
financial_health_prompt_sha256: 0a7f61736a0b9867773ff7db9508225e9a13499f7330cee4b00e8cebbb7ed76d
financial_health_seed: 1060270
financial_health_response_model: financial-lora-w4a16
financial_health_finish_reason: stop
financial_health_completion_tokens: 93
risk_factors_prompt_sha256: f9aa231716879b9188636cec364f613a0e910dd13e3e5de132fec68b9fe09366
risk_factors_seed: 1060271
risk_factors_response_model: financial-lora-w4a16
risk_factors_finish_reason: stop
risk_factors_completion_tokens: 403

## Stock data

{
  "ticker": "SANA",
  "company_name": "Sana Biotechnology, Inc.",
  "current_price": 3.08,
  "currency": "USD",
  "market_cap": 922030720.0,
  "forward_pe": -5.54845,
  "week_52_high": 6.55,
  "week_52_low": 2.61,
  "net_income": -211822000.0,
  "profit_margin": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

<!-- replay-section: Financial Health -->
### Financial Health
Sana Biotechnology, Inc., trades under the ticker symbol "SANA" on the Nasdaq Global Select Market. It carries a market capitalization of $9.2 billion and a forward P/E ratio of -5.5x. The company reports net income of -$2.1 billion and a net profit margin of 0%. The sector in which Sana Biotechnology operates is Healthcare, specifically within the biotechnology industry.

<!-- replay-section: Risk Factors -->
### Primary Risk Factors Disclosed

The company has disclosed numerous material risk factors, which can be organized into several key categories:

#### 1. **Technology and Development Risks**
   - The cell engineering platforms are based on novel, unproven technologies that may not result in approvable or marketable products.
   - Inability to successfully identify, develop, and commercialize product candidates, or experiencing significant delays in doing so.
   - Preclinical testing may be delayed or unsuccessful, harming the ability to commence clinical trials.
   - Clinical trials may fail to demonstrate that product candidates meet regulatory requirements for safety, purity, potency, and efficacy.

#### 2. **Financial and Operational Risks**
   - Substantial doubt regarding the company's ability to continue as a going concern.
   - Need for additional funding to finance operations, with potential inability to raise capital on acceptable terms.
   - Potential need to delay, reduce, or eliminate product development programs or commercialization efforts.
   - Difficulties in managing growth and expansion of operations.

#### 3. **Personnel and Strategic Risks**
   - Dependence on retaining key personnel and recruiting qualified staff.
   - Inability to realize benefits from acquired or in-licensed technologies.
   - Failure to enter into or realize benefits from strategic relationships.

#### 4. **Manufacturing and Supply Chain Risks**
   - Complex manufacturing processes that may encounter production difficulties.
   - Exposure to supply chain risks for materials required in manufacturing.
   - Reliance on third parties (CDMOs, CROs) whose failures could harm the business.

#### 5. **Regulatory, Intellectual Property, and Security Risks**
   - Extensive regulatory requirements and lengthy, unpredictable approval processes.
   - Risks related to human stem cell use, including ethical and legal implications.
   - Inability to adequately protect intellectual property rights.
   - Dependence on licensed intellectual property from third parties.
   - Potential computer system failures or security breaches.
